Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 22;10(4):00372-2024.
doi: 10.1183/23120541.00372-2024. eCollection 2024 Jul.

Heterogeneity in non-cystic fibrosis bronchiectasis: insights from ASPEN trial participants

Melissa H Ross  1 , Shijing Jia  2
Affiliations
Editorial

Heterogeneity in non-cystic fibrosis bronchiectasis: insights from ASPEN trial participants

Melissa H Ross et al. ERJ Open Res. .

Abstract

ASPEN trial participant characteristics highlight the heterogeneity of non-cystic fibrosis bronchiectasis and global variations in clinical practice patterns https://bit.ly/447XeP0.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M.H. Ross reports receiving support for attending meetings and/or travel from the Cystic Fibrosis Foundation outside the submitted work. S. Jia reports receiving grants paid to their institution from the Cystic Fibrosis Foundation (research grant), Cure CF, Inc. (research grant), Vertex Inc. (clinical trials support) and INSMED Inc. (clinical trials support), outside the submitted work; royalties paid to them from UpToDate, outside the submitted work; consulting fees paid to their institution from Insmed, paid to them from Verona Pharma, outside the submitted work; and participation on a data safety monitoring or advisory board for the Cystic Fibrosis Foundation, outside the submitted work.

Comment on

References

    1. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383–1393. doi:10.1056/NEJMra012519 - DOI - PubMed
    1. Chalmers JD, Aliberti S, Filonenko A, et al. . Characterization of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med 2018; 197: 1410–1420. doi:10.1164/rccm.201711-2202OC - DOI - PubMed
    1. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62: 360–367. doi:10.1136/thx.2006.060889 - DOI - PMC - PubMed
    1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45: 1446–1462. doi:10.1183/09031936.00119114 - DOI - PubMed
    1. Jia S, Taylor-Cousar JL. Cystic fibrosis modulator therapies. Annu Rev Med 2023; 74: 413–426. doi:10.1146/annurev-med-042921-021447 - DOI - PubMed

LinkOut - more resources